222 related articles for article (PubMed ID: 23620080)
21. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.
Jeromin S; Weissmann S; Haferlach C; Dicker F; Bayer K; Grossmann V; Alpermann T; Roller A; Kohlmann A; Haferlach T; Kern W; Schnittger S
Leukemia; 2014 Jan; 28(1):108-17. PubMed ID: 24113472
[TBL] [Abstract][Full Text] [Related]
22. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
Rodríguez-Vicente AE; Díaz MG; Hernández-Rivas JM
Cancer Genet; 2013 Mar; 206(3):49-62. PubMed ID: 23531595
[TBL] [Abstract][Full Text] [Related]
23. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome.
Rossi D; Rasi S; Spina V; Fangazio M; Monti S; Greco M; Ciardullo C; Famà R; Cresta S; Bruscaggin A; Laurenti L; Martini M; Musto P; Forconi F; Marasca R; Larocca LM; Foà R; Gaidano G
Br J Haematol; 2012 Aug; 158(3):426-9. PubMed ID: 22571487
[No Abstract] [Full Text] [Related]
24. On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort.
Cortese D; Sutton LA; Cahill N; Smedby KE; Geisler C; Gunnarsson R; Juliusson G; Mansouri L; Rosenquist R
Leukemia; 2014 Mar; 28(3):710-3. PubMed ID: 24217197
[No Abstract] [Full Text] [Related]
25. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
[TBL] [Abstract][Full Text] [Related]
26. Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: different genetic mechanisms but equivalent poorer clinical outcome.
Puiggros A; Venturas M; Salido M; Blanco G; Fernandez-Rodriguez C; Collado R; Valiente A; Ruiz-Xivillé N; Carrió A; Ortuño FJ; Luño E; Calasanz MJ; Ardanaz MT; Piñán MÁ; Talavera E; González MT; Ortega M; Marugán I; Ferrer A; Gimeno E; Bellosillo B; Delgado J; Hernández JÁ; Hernández-Rivas JM; Espinet B; ;
Genes Chromosomes Cancer; 2014 Sep; 53(9):788-97. PubMed ID: 24915757
[TBL] [Abstract][Full Text] [Related]
27. Prognostic correlation of NOTCH1 and SF3B1 mutations with chromosomal abnormalities in chronic lymphocytic leukemia patients.
Sadria R; Motamed N; Saberi Anvar M; Mehrabani Yeganeh H; Poopak B
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1757. PubMed ID: 36411516
[TBL] [Abstract][Full Text] [Related]
28. Telomere length and its correlation with gene mutations in chronic lymphocytic leukemia in a Korean population.
Song DY; Kim JA; Jeong D; Yun J; Kim SM; Lim K; Park SN; Im K; Choi S; Yoon SS; Lee DS
PLoS One; 2019; 14(7):e0220177. PubMed ID: 31335885
[TBL] [Abstract][Full Text] [Related]
29. A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia.
Chauzeix J; Pastoret C; Donaty L; Gachard N; Fest T; Feuillard J; Rizzo D
Int J Lab Hematol; 2021 Aug; 43(4):683-692. PubMed ID: 33325634
[TBL] [Abstract][Full Text] [Related]
30. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.
Rossi D; Spina V; Bomben R; Rasi S; Dal-Bo M; Bruscaggin A; Rossi FM; Monti S; Degan M; Ciardullo C; Serra R; Zucchetto A; Nomdedeu J; Bulian P; Grossi A; Zaja F; Pozzato G; Laurenti L; Efremov DG; Di-Raimondo F; Marasca R; Forconi F; Del Poeta G; Gaidano G; Gattei V
Blood; 2013 Jun; 121(24):4902-5. PubMed ID: 23637131
[TBL] [Abstract][Full Text] [Related]
31. Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation.
Onaindia A; Gómez S; Piris-Villaespesa M; Martínez-Laperche C; Cereceda L; Montes-Moreno S; Batlle A; de Villambrosia SG; Pollán M; Martín-Acosta P; González-Rincón J; Menarguez J; Alvés J; Rodriguez-Pinilla SM; García JF; Mollejo M; Fraga M; García-Marco JA; Piris MA; Sánchez-Beato M
Haematologica; 2015 May; 100(5):e200-3. PubMed ID: 25552700
[No Abstract] [Full Text] [Related]
32. Predicting treatment outcomes in CLL.
Wiestner A
Blood; 2014 May; 123(21):3212-4. PubMed ID: 24855188
[TBL] [Abstract][Full Text] [Related]
33. UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?
Bhoi S; Baliakas P; Cortese D; Mattsson M; Engvall M; Smedby KE; Juliusson G; Sutton LA; Mansouri L
Haematologica; 2016 Feb; 101(2):e63-5. PubMed ID: 26589911
[No Abstract] [Full Text] [Related]
34. Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.
Ouillette P; Saiya-Cork K; Seymour E; Li C; Shedden K; Malek SN
Clin Cancer Res; 2013 Jun; 19(11):2893-904. PubMed ID: 23620403
[TBL] [Abstract][Full Text] [Related]
35. CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.
Dal Bo M; Bulian P; Bomben R; Zucchetto A; Rossi FM; Pozzo F; Tissino E; Benedetti D; Bittolo T; Nanni P; Cattarossi I; Zaina E; Chivilò H; Degan M; Zaja F; Pozzato G; Chiarenza A; Di Raimondo F; Del Principe MI; Del Poeta G; Rossi D; Gaidano G; Gattei V
Leukemia; 2016 Oct; 30(10):2011-2018. PubMed ID: 27109509
[TBL] [Abstract][Full Text] [Related]
36. Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia.
Rasi S; Khiabanian H; Ciardullo C; Terzi-di-Bergamo L; Monti S; Spina V; Bruscaggin A; Cerri M; Deambrogi C; Martuscelli L; Biasi A; Spaccarotella E; De Paoli L; Gattei V; Foà R; Rabadan R; Gaidano G; Rossi D
Haematologica; 2016 Apr; 101(4):e135-8. PubMed ID: 26819056
[No Abstract] [Full Text] [Related]
37. LPL gene expression is associated with poor prognosis in CLL and closely related to NOTCH1 mutations.
Kristensen L; Kristensen T; Abildgaard N; Royo C; Frederiksen M; Mourits-Andersen T; Campo E; Møller MB
Eur J Haematol; 2016 Aug; 97(2):175-82. PubMed ID: 26558352
[TBL] [Abstract][Full Text] [Related]
38. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
Nabhan C; Raca G; Wang YL
JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
[TBL] [Abstract][Full Text] [Related]
39. Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53.
Zent CS; Burack WR
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):119-24. PubMed ID: 25696844
[TBL] [Abstract][Full Text] [Related]
40. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
Guièze R; Robbe P; Clifford R; de Guibert S; Pereira B; Timbs A; Dilhuydy MS; Cabes M; Ysebaert L; Burns A; Nguyen-Khac F; Davi F; Véronèse L; Combes P; Le Garff-Tavernier M; Leblond V; Merle-Béral H; Alsolami R; Hamblin A; Mason J; Pettitt A; Hillmen P; Taylor J; Knight SJ; Tournilhac O; Schuh A
Blood; 2015 Oct; 126(18):2110-7. PubMed ID: 26316624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
